Tema Oncology ETF (NASDAQ:CANC – Get Free Report) saw a large decline in short interest in the month of August. As of August 14th, there was short interest totaling 10,698 shares, a decline of 47.3% from the July 30th total of 20,291 shares. Based on an average daily volume of 17,651 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.2% of the shares of the company are sold short.
Institutional Investors Weigh In On Tema Oncology ETF
Several institutional investors have recently modified their holdings of the stock. Roxbury Financial LLC purchased a new stake in Tema Oncology ETF during the first quarter worth $34,000. Jane Street Group LLC acquired a new position in Tema Oncology ETF in the first quarter valued at about $213,000. LPL Financial LLC purchased a new position in Tema Oncology ETF in the 4th quarter valued at approximately $278,000. Flow Traders U.S. LLC purchased a new position in Tema Oncology ETF in the third quarter valued at $630,000. Finally, Thrivent Financial for Lutherans boosted its position in shares of Tema Oncology ETF by 891.1% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,461,649 shares of the company’s stock valued at $50,747,000 after purchasing an additional 1,314,177 shares during the period.
Tema Oncology ETF Stock Performance
CANC traded down $1.27 during midday trading on Friday, hitting $43.52. The stock had a trading volume of 22,433 shares, compared to its average volume of 31,679. The company has a market cap of $207.59 million, a P/E ratio of 20.39 and a beta of 0.68. Tema Oncology ETF has a 1 year low of $26.52 and a 1 year high of $47.00. The business has a fifty day moving average of $41.87 and a 200 day moving average of $38.84.
About Tema Oncology ETF
The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.
See Also
- Five stocks we like better than Tema Oncology ETF
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for Tema Oncology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tema Oncology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
